With one-third the dose, kids develop adult-level antibody protection; results for children under 5 expected by year-end.

Pfizer said Monday its COVID-19 vaccine works for children ages 5 to 11, and expects results in the next few months from its tests on children as young as 6 months. The company said it will seek U.S. authorization for child vaccination.

The vaccine made by Pfizer and its German partner BioNTech already is available for anyone 12 and older. But with kids now back in school and the extra-contagious delta variant causing a huge jump in pediatric infections, many parents are anxiously awaiting vaccinations for their younger children.

For elementary school-aged kids, Pfizer tested a much lower dose — a third of the amount that’s in each shot given now. Yet after their second dose, children ages 5 to 11 developed coronavirus-fighting antibody levels just as strong as teenagers and young adults getting the regular-strength shots, Dr. Bill Gruber, a Pfizer senior vice president, told The Associated Press.

The kid dosage also proved safe, with similar or fewer temporary side effects — such as sore arms, fever or achiness — that teens experience, he said.

© Copyright LaPresse